Roche to provide HIV/AIDS tests for Early Infant Diagnosis in South Africa
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has been awarded an exclusive contract by the National Health Laboratory Services (NHLS) in South Africa for the support of the Early Infant Diagnosis (EID) Programme.
New Senior Executives appointed at Sanofi
- Details
- Category: Sanofi
Sanofi (EURONEXT : SAN ; NYSE : SNY) announced the appointment of Greg Irace, currently President and CEO of Sanofi's US operations, to the newly created role of Senior Vice President, Global Services.
Bristol-Myers Squibb to Acquire Amira Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Amira Pharmaceuticals, Inc., announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.
FDA approves new medicine BRILINTA (ticagrelor) for use in the US
- Details
- Category: AstraZeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack (myocardial infarction [MI]) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.
Pfizer To Acquire Icagen
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen's fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share.
FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) reported the outcome of the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin.
Novartis delivers strong financial results and four major approvals
- Details
- Category: Novartis
Novartis' net sales rose 27% (+19% cc) to USD 14.9 billion. Currency benefited sales by 8% as the US dollar weakened against most currencies. Recently launched products grew 46% over the previous-year quarter, contributing USD 3.8 billion to total net sales for the Group.
More Pharma News ...
- Abbott Confirms Long-Term Commitment to HIV Care
- Novartis begins shipment of Fluvirin® seasonal influenza vaccine to US customers
- XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
- Roche provides update from FDA hearing on Avastin for metastatic breast cancer
- Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
- Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis
- Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition